Crossject
UEI: NLXZHCL3NLL3
• CAGE: FBEF0
Overview
Awardee Type
Parent
(1 child)
Company Description
Crossject developed ZENEO®, a world-leading needle-free injection platform, designed to improve patients’ safety and comfort and to enable a better observance of treatments. Needleless free injection of medicinal solution.
Name
Crossject
Website
Headquarters
Dijon, BOURGOGNE-FRANCHE-COMTE
France
France
Most Recent Award
June 22, 2022
Calculating
Federal contract recipient
CROSSJECT SA
(UEI NLXZHCL3NLL3, CAGE FBEF0)
is headquartered in Dijon BOURGOGNE-FRANCHE-COMTE.
Its primary registered NAICS is 541714 Research and Development in Biotechnology (except Nanobiotechnology).
The corporation
was founded in August 2001 and
federally registered in
May 2019.
Federal Award Analysis
Crossject federal award history
$-
Contracts
$-
Subcontracts
$-
Grants
$-
Subgrants
$-
Total
No Results
Calculating
Calculating
No Results
Calculating
Calculating
No Results
Calculating
Calculating
| Year | Contracts | Subcontracts | Grants | Subgrants |
|---|
No Results
Calculating
Calculating
No Results
Calculating
Calculating
Federal Registration and Certifications
Legal Name
CROSSJECT SA
UEI
NLXZHCL3NLL3
CAGE Code
FBEF0
SBA Certifications
None
Self Certifications
None
Entity Structure
Corporate Entity (Not Tax Exempt)
Purpose of Registration
Federal Contracts and Assistance
Date Founded
Aug. 8, 2001
Initial Registration
May 14, 2019
Last Registration
Oct. 9, 2025
Registration Activation
Oct. 9, 2025
Registration Expiration
Oct. 9, 2026
Fiscal Year End
December 31
Reported Entity Types
For Profit Organization
Manufacturer of Goods
Manufacturer of Goods
Country of Incorporation
FRA
Employees
<500
Reported NAICS
Accepts Credit Cards
No